U.S. markets closed
  • S&P 500

    4,395.64
    +41.45 (+0.95%)
     
  • Dow 30

    34,258.32
    +338.48 (+1.00%)
     
  • Nasdaq

    14,896.85
    +150.45 (+1.02%)
     
  • Russell 2000

    2,218.56
    +32.38 (+1.48%)
     
  • Crude Oil

    71.98
    -0.25 (-0.35%)
     
  • Gold

    1,768.40
    -10.40 (-0.58%)
     
  • Silver

    23.03
    +0.17 (+0.73%)
     
  • EUR/USD

    1.1696
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • GBP/USD

    1.3623
    +0.0004 (+0.03%)
     
  • USD/JPY

    109.7860
    +0.0080 (+0.01%)
     
  • BTC-USD

    43,516.97
    +3,028.26 (+7.48%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

NanoViricides' Broad-Spectrum Antiviral Drug Candidate Shows Encouraging Action In Preclinical Studies For COVID-19

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • NanoViricides Inc (NYSE: NNVC) has reported data from animal studies evaluating its broad-spectrum antiviral drug candidate NV-CoV-2 to treat COVID-19 infections. 

  • The treatment candidate was well tolerated in safety pharmacology studies in both rat and non-human primate models. Multiple injections of NV-CoV-2 were also well-tolerated in an extensive non-GLP study in rats performed by AR Biosystems Inc.

  • The studies showed that intravenous (IV) administration of NV-CoV-2 at doses of 25, 50, and 100 mg/kg did not affect rats' respiratory function. IV infusion at 25, 37.5, and 50 mg/kg did not have any toxicologic effects on cardiac rhythm or ECG morphology in cynomolgus monkeys. No significant effects on blood pressure and heart rate were observed.

  • Pre-IND application submission to the US FDA is up next to obtain guidance regarding human clinical trials.

  • Price Action: NNVC gained 6.8% at $5.03 in premarket trading on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.